N-sulfoöxy-2-aminofluorene is the major ultimate electrophilic and carcinogenic metabolite of N-hydroxy-2-acetylaminofluorene in the livers of infant male C57BL/6J x C3H/HeJ F1 (B6C3F1) mice.
The hepatic DNA of 12-day-old male B6C3F1 (C57BL/6J X C3H/HeJ) mice given an i.p. dose of 0.06 or 0.11 mumol/g body weight of N-hydroxy-[3H]-2-acetylaminofluorene (N-hydroxy-AAF) contained at 9 h approximately 3 or 6 pmol of N-(deoxyguanosin-8-yl)-2-aminofluorene adducts per mg. Together the level of the two acetylated adducts N-(deoxyguanosin-8-yl)-2-acetylaminofluorene and 3-(deoxyguanosin-N2-yl)-2-acetylaminofluorene was less than or equal to 10% of this amount. The same doses of unlabeled carcinogen induced by 10 months a 100% incidence of hepatomas with averages of 10 and 15 hepatomas per mouse, respectively. Injection of 0.04 mumol/g body weight of pentachlorophenol (PCP) 45 min before the dose of N-hydroxy-AAF decreased the number of adducts in the DNA by 90% and the average number of hepatomas per liver by 80-90%. As compared to their normal male littermates, male brachymorphic B6C3F2 mice, which are deficient in hepatic 3'-phosphoadenosine-5'-phosphosulfate (PAPS), treated with N-hydroxy-AAF formed only 25% as many hepatic DNA adducts and developed only 10% as many hepatomas. Hepatic cytosols from 12-day-old B6C3F1 mice contained PAPS-dependent sulfotransferase activity for N-hydroxy-2-aminofluorene (N-hydroxy-AF), a previously unrecognized activity, as well as sulfotransferase activity for N-hydroxy-AAF; both activities were inhibited 60% by 1 microM and greater than or equal to 80% by 10 microM PCP. Cytosolic acetyl coenzyme A-dependent acetyltransferase activity for N-hydroxy-AF, cytosolic N,O-acyltransferase activity for N-hydroxy-AAF, and microsomal deacetylase for N-hydroxy-AAF were not significantly inhibited by PCP under these conditions. The above data strongly indicate that N-sulfoöxy-2-aminofluorene is the major ultimate electrophilic and carcinogenic metabolite of N-hydroxy-AAF in the livers of infant male B6C3F1 mice.
D015073:2-Acetylaminofluorene / Q000031:analogs & derivatives*; D000217:Acyltransferases / Q000378:metabolism; D000818:Animals; D002273:Carcinogens / Q000302:isolation & purification*; D003433:Crosses, Genetic; D003600:Cytosol / Q000201:enzymology; D004247:DNA / Q000378:metabolism; D005260:Female; D006881:Hydroxyacetylaminofluorene / Q000378:metabolism*; D008099:Liver / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008817:Mice, Mutant Strains; D010641:Phenotype; D051381:Rats; D011916:Rats, Inbred F344; D011919:Rats, Inbred Strains; D013466:Sulfurtransferases / Q000378:metabolism; D014316:Tritium
D002273:Carcinogens; D014316:Tritium; D006881:Hydroxyacetylaminofluorene; D004247:DNA; D015073:2-Acetylaminofluorene; D000217:Acyltransferases; D013466:Sulfurtransferases